Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuing versus withdrawing adalimumab to maintain remission in non-radiographic axial spondyloarthritis
2012-000646-35Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in axial spondyloarthritis (axSpA) (2 arms), sponsored by AbbVie Inc. Started Mar 2013; status: completed.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2012-000646-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000646-35.